Nyxoah S.A.
NYXH
$-0.12
Change (1 day)
$20.00
Year High
$4.00
Year Low
Categories
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
P/S ratio for Nyxoah S.A. (NYXH)
P/S ratio as of 2023: 27.00
According to Nyxoah S.A.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 27.00. At the end of 2022 the company had a P/S ratio of 39.01.
P/S ratio history for Nyxoah S.A. from 2017 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 27.00 |
| 2022 | 39.01 |
| 2021 | 564.83 |
| 2020 | 5150.53 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |